Cancer diagnosis firm Grail could be re-joining Illumina, the company it was spun out of in 2016, despite filing for an initial public offering (IPO) just a few days ago.
Angle’s liquid biopsy system has been used in new cancer research that could provide a novel way to treat breast cancer and other tumours, by stopping or suppressing their spread from the o